ESMO 2024: Treatment of uHCC - Episode 3

Current Treatment in First Line – IO + TKI or IO + IO

October 18, 2024

Richard Finn, MD, Olatunji Alese, MD, Daneng Li, MD, Anthony El-Khoueiry, MD, Masatoshi Kudo, MD, PhD, Steven Chan, MD

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP. 2: Treatment Decisions Based on BLCL Stage

Now Viewing

EP. 3: Current Treatment in First Line – IO + TKI or IO + IO

EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line

EP. 5: EMERALD-1 Study Results

EP. 6: Discussion and Summary

EP. 7: LEAP-012 Study Results

EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

Video content above is prompted by the following:

What is the role of tyrosine kinase inhibitors in first-line treatment?